Richard E Champlin
M.D. Anderson Cancer Center · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard E Champlin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:01 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03622788 · Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantM.D. Anderson Cancer Center · active not recruiting · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia · principal investigator
- Ph1NCT02423915 · Fucosylated T Cells for Graft Versus Host Disease (GVHD) PreventionM.D. Anderson Cancer Center · completed · Leukemia, Lymphoma · principal investigator
- Ph1/Ph2NCT01875237 · Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide GeneM.D. Anderson Cancer Center · terminated · Leukemia, Myeloma, Myeloproliferative Diseases · principal investigator
- Ph1/Ph2NCT01823198 · Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesM.D. Anderson Cancer Center · completed · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia · principal investigator
- Ph2NCT01518153 · Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)M.D. Anderson Cancer Center · terminated · Leukemia, Lymphoma, Myeloma · principal investigator
- Ph3NCT01471444 · Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection · principal investigator
- Ph2NCT01390402 · Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATGM.D. Anderson Cancer Center · completed · Leukemia, Chronic Myelogenous Leukemia · principal investigator
- Ph3NCT00887068 · Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)M.D. Anderson Cancer Center · completed · Leukemia, AML, MDS · principal investigator
- Ph1NCT00866346 · PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic TransplantationM.D. Anderson Cancer Center · withdrawn · Chronic Myelogenous Leukemia · study chair
- Ph2NCT00813124 · Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)M.D. Anderson Cancer Center · completed · Stem Cell Transplantation, Leukemia · principal investigator
- Ph1/Ph2NCT00506857 · Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell SupportM.D. Anderson Cancer Center · completed · Hematologic Malignancies · principal investigator
- Ph2NCT00502905 · Busulfan and Fludarabine in Patients With AML and MDSM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT00499889 · Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML PatientsM.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1NCT00473551 · Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid MalignanciesM.D. Anderson Cancer Center · terminated · Leukemia, Lymphoma, Myeloma · principal investigator
- Ph3NCT00469144 · IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Leukemia, Acute Myeloid Leukemia · principal investigator
- Ph2NCT00469014 · Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid LeukemiaM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia · principal investigator
- Ph1NCT00402558 · Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Leukemia · principal investigator
- Ph2NCT00002844 · Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Leukemia · study chair
- Ph2NCT00002829 · Bone Marrow Transplantation in Treating Patients With LymphomaM.D. Anderson Cancer Center · completed · Lymphoma · study chair
- Ph3NCT00002835 · Combination Chemotherapy in Treating Patients With LymphomaM.D. Anderson Cancer Center · completed · Lymphoma · study chair
- Ph2NCT00038857 · Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant DiseasesM.D. Anderson Cancer Center · completed · Leukemia, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- 13 Stem Cell Transplantation and Cellular TherapyP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 · $18,707 awarded in 2019Grant number is on one of their registry trials
- Research Training in Academic Medical OncologyT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2015 to 2016 · $490,275 awarded in 2016Same name and institution; not confirmed by an ID
- AdministrationP01CA049639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 1996 to 2014 · $195,813 awarded in 2014Grant number is on one of their registry trials
- Improving the Outcomes of Stem Cell TransplantationU10HL069334 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2011 to 2013 · $163,530 awarded in 2013Same name and institution; not confirmed by an ID
- Hematopoietic Transplantation for AMLP01CA055164 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 1996 to 2011 · $350,327 awarded in 2011Same name and institution; not confirmed by an ID
- Blood Marrow Transplant Clinical Trials Research NetworkU01HL069334 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2009 to 2010 · $150,504 awarded in 2010Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHDR44CA192601 · NCI · TARGAZYME, INC. · PI JoAnn Flaim · fiscal years 2015 to 2016Named on NCT02423915
- Rebuilding Immunity for SurvivalP01CA100265 · NCI · DANA-FARBER CANCER INST · PI Lee Marshall Nadler · fiscal years 2003 to 2005Named on NCT00402558
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 12:01 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed